Urendia 20 mg (Tablet)
Unit Price: ৳ 150.00 (1 x 10: ৳ 1,500.00)
Strip Price: ৳ 1,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Indications
- Reduces the risk of sustained eGFR decline
- Reduces risk of end-stage kidney disease
- Reduces risk of cardiovascular death
- Reduces risk of nonfatal myocardial infarction
- Reduces risk of hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Pharmacology
- Nonsteroidal
- Selective antagonist of the mineralocorticoid receptor (MR)
- Blocks MR mediated sodium reabsorption
- Has high potency and selectivity for the MR
- Completely absorbed after oral administration
- Undergoes metabolism resulting in absolute bioavailability of 44%
- Metabolized primarily by CYP3A4
- Excreted about 80% in urine
Dosage & Administration
- Recommended starting dosage of 10 mg or 20 mg orally once daily
- Tablets may be taken with or without food
- Monitoring for serum potassium levels
- Dose adjustment based on serum potassium levels
- Instructions for missed doses
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Monitoring for serum potassium with moderate and weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Adverse reactions include hyperkalemia
- Adverse reactions include hypotension
- Adverse reactions include hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Animal studies have shown developmental toxicity
- No data on presence in human milk
- Avoid breastfeeding during treatment and for 1 day after treatment
Precautions & Warnings
- Can cause hyperkalemia
- Risk increases with decreasing kidney function
- Measure serum potassium and eGFR before initiation of treatment
- Do not initiate if serum potassium is > 5.0 mEq/L
- More frequent monitoring may be necessary for patients at risk
Use in Special Populations
- Safety and efficacy not established in patients below 18 years of age
- No overall differences in safety or efficacy observed in geriatric patients
- Avoid use in patients with severe hepatic impairment
- No dosage adjustment required in mild or moderate hepatic impairment
Overdose Effects
- Immediate interruption of treatment in the event of suspected overdose
- Most likely manifestation is hyperkalemia
- Standard treatment for hyperkalemia should be initiated
- Unlikely to be efficiently removed by hemodialysis given its fraction bound to plasma proteins of about 90%
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Keep below 30°C, away from light & moisture
- Keep out of the reach of children